Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms.
Journal
NEJM evidence
ISSN: 2766-5526
Titre abrégé: NEJM Evid
Pays: United States
ID NLM: 9918317485806676
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
medline:
4
8
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
ppublish
Résumé
Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant (XDR) The OVERCOME (Colistin Monotherapy versus Combination Therapy) trial was an international, randomized, double-blind, placebo-controlled trial. We randomly assigned participants to receive colistin (5 mg/kg once followed by 1.67 mg/kg every 8 hours) in combination with either meropenem (1000 mg every 8 hours) or matching placebo for the treatment of pneumonia and/or BSI caused by XDR A. Between 2012 and 2020, a total of 464 participants were randomly assigned to treatment, and 423 eligible patients comprised the modified intention-to-treat population. Combination therapy with colistin and meropenem was not superior to colistin monotherapy for the treatment of pneumonia or BSI caused by these pathogens. (Funded by the National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases protocol 10-0065; ClinicalTrials.gov number, NCT01597973.).
Sections du résumé
BACKGROUND
BACKGROUND
Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant (XDR)
METHODS
METHODS
The OVERCOME (Colistin Monotherapy versus Combination Therapy) trial was an international, randomized, double-blind, placebo-controlled trial. We randomly assigned participants to receive colistin (5 mg/kg once followed by 1.67 mg/kg every 8 hours) in combination with either meropenem (1000 mg every 8 hours) or matching placebo for the treatment of pneumonia and/or BSI caused by XDR A.
RESULTS
RESULTS
Between 2012 and 2020, a total of 464 participants were randomly assigned to treatment, and 423 eligible patients comprised the modified intention-to-treat population.
CONCLUSIONS
CONCLUSIONS
Combination therapy with colistin and meropenem was not superior to colistin monotherapy for the treatment of pneumonia or BSI caused by these pathogens. (Funded by the National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases protocol 10-0065; ClinicalTrials.gov number, NCT01597973.).
Identifiants
pubmed: 37538951
doi: 10.1056/evidoa2200131
pmc: PMC10398788
mid: NIHMS1875033
doi:
Banques de données
ClinicalTrials.gov
['NCT01597973']
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201600049C
Pays : United States
Références
Antimicrob Agents Chemother. 2014 Sep;58(9):5598-601
pubmed: 24982065
Open Forum Infect Dis. 2019 Jul 28;6(8):ofz344
pubmed: 31660388
Open Forum Infect Dis. 2020 Sep 30;7(11):ofaa461
pubmed: 33209951
N Engl J Med. 2019 Feb 21;380(8):791-793
pubmed: 30786196
Clin Infect Dis. 2013 Aug;57(3):349-58
pubmed: 23616495
Epidemiol Infect. 2013 Jun;141(6):1214-22
pubmed: 22954403
Pharmacotherapy. 2019 Jan;39(1):10-39
pubmed: 30710469
Infect Control Hosp Epidemiol. 2021 Mar;42(3):305-310
pubmed: 32993829
Clin Infect Dis. 2018 Jan 6;66(2):163-171
pubmed: 29020404
Infect Dis Ther. 2018 Dec;7(4):439-455
pubmed: 30270406
Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa054
pubmed: 32154325
Clin Infect Dis. 2020 Jul 11;71(2):304-310
pubmed: 31545346
J Antimicrob Chemother. 2021 Jul 15;76(8):2182-2185
pubmed: 33969419
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Clin Infect Dis. 2022 Aug 25;75(2):187-212
pubmed: 35439291
Clin Microbiol Infect. 2022 Apr;28(4):521-547
pubmed: 34923128
Lancet Infect Dis. 2018 Apr;18(4):391-400
pubmed: 29456043
Lancet Infect Dis. 2020 Jun;20(6):731-741
pubmed: 32151332
Curr Infect Dis Rep. 2019 Sep 9;21(10):39
pubmed: 31501948
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28559250
Crit Care. 2004 Aug;8(4):R204-12
pubmed: 15312219